Skip to main content
. 2020 Aug 11;26:e924858-1–e924858-15. doi: 10.12659/MSM.924858

Table 2.

Univariate logistic regression for analyzing the risk factors for early death in patients with IV breast cancer.

Subject characteristics Total early death Cancer specific early death Non-cancer specific early death
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
Age
 <50 Ref 1.0 Ref 1.0 Ref 1.0
 50–59 1.57 (1.40–1.74) <0.001 1.47 (1.31–1.66) <0.001 1.63 (1.31–2.03) <0.001
 60–69 1.99 (1.80–2.22) <0.001 1.73 (1.54–1.94) <0.001 2.30 (1.87–2.83) <0.001
 70–79 2.92 (2.62–3.26) <0.001 2.26 (2.00–2.54) <0.001 3.49 (2.83–4.30) <0.001
 ≥80 5.11 (4.55–5.74) <0.001 3.18 (2.81–3.60) <0.001 5.83 (4.74–7.17) <0.001
Marital status
 Married Ref 1.0 Ref 1.0 Ref 1.0
 Unmarried 1.80 (1.69–1.92) <0.001 1.67 (1.55–1.79) <0.001 1.60 (1.43–1.78) <0.001
Race
 White Ref 1.0 Ref 1.0 Ref 1.0
 Black 1.36 (1.26–1.48) <0.001 1.29 (1.18–1.41) <0.001 1.29 (1.13–1.47) <0.001
 Others 0.80 (0.71–0.91) 0.001 0.83 (0.72–0.95) 0.007 0.83 (0.67–1.03) 0.089
Insurance
 Insured Ref 1.0 Ref 1.0 Ref 1.0
 Uninsured 1.50 (1.29–1.74) <0.001 1.81 (1.55–2.11) <0.001 0.65 (0.47–0.88) 0.006
Subtypes
 Luminal A Ref 1.0 Ref 1.0 Ref 1.0
 Luminal B 0.88 (0.79–0.98) 0.017 0.99 (0.88–1.11) 0.864 0.67 (0.55–0.82) <0.001
 HER2 enriched 1.51 (1.33–1.71) <0.001 1.57 (1.37–1.80) <0.001 1.14 (0.92–1.42) 0.234
 Triple negative 4.06 (3.68–4.48) <0.001 3.49 (3.15–3.87) <0.001 2.26 (1.95–2.62) <0.001
Grade
 Grade I Ref 1.0 Ref 1.0 Ref 1.0
 Grade II 1.50 (1.28–1.76) <0.001 1.59 (1.32–1.92) <0.001 1.18 (0.91–1.53) 0.214
 Grade III 2.43 (2.08–2.84) <0.001 2.67 (2.22–3.21) <0.001 1.40 (1.08–1.80) 0.010
 Grade IV 3.71 (2.44–5.65) <0.001 4.34 (2.79–6.75) <0.001 1.34 (0.63–2.86) 0.454
Tumor site
 UOQ Ref 1.0 Ref 1.0 Ref 1.0
 LOQ 0.85 (0.72–1.00) 0.051 0.84 (0.70–1.02) 0.072 0.92 (0.70–1.22) 0.564
 LIQ 0.87 (0.72–1.06) 0.173 0.81 (0.64–1.01) 0.058 1.09 (0.80–1.49) 0.577
 UIQ 0.92 (0.79–1.07) 0.272 0.91 (0.77–1.08) 0.271 0.98 (0.76–1.26) 0.852
 CEN 0.97 (0.84–1.13) 0.712 0.99 (0.83–1.17) 0.870 0.95 (0.73–1.23) 0.705
 Others 1.06 (0.96–1.17) 0.287 1.04 (0.93–1.16) 0.477 1.06 (0.90–1.26) 0.472
Laterality
 Left-sided Ref 1.0 Ref 1.0 Ref 1.0
 Right-sided 0.98 (0.92–1.05) 0.534 0.97 (0.91–1.04) 0.419 1.01 (0.91–1.13) 0.848
 One side, NOS 1.45 (0.94–2.24) 0.090 1.63 (1.04–2.56) 0.033 0.83 (0.36–1.90) 0.655
 Paired sides 1.73 (1.51–1.98) <0.001 1.50 (1.30–1.73) <0.001 1.67 (1.36–2.04) <0.001
Tumor size
 0–2 cm Ref 1.0 Ref 1.0 Ref 1.0
 2–5 cm 1.09 (0.98–1.21) 0.100 1.29 (1.15–1.45) <0.001 0.77 (0.66–0.90) 0.001
 >5 cm 1.33 (1.20–1.48) <0.001 1.80 (1.59–2.03) <0.001 0.60 (0.51–0.71) <0.001
N stage
 N0 Ref 1.0 Ref 1.0 Ref 1.0
 N1 0.73 (0.67–0.79) <0.001 0.92 (0.83–1.01) 0.065 0.51 (0.44–0.59) <0.001
 N2 0.63 (0.55–0.72) <0.001 0.76 (0.66–0.89) <0.001 0.52 (0.41–0.65) <0.001
 N3 1.00 (0.92–1.09) 0.976 1.21 (1.10–1.33) <0.001 0.67 (0.58–0.77) <0.001
Bone Met
 No Ref 1.0 Ref 1.0 Ref 1.0
 Yes 0.72 (0.67–0.77) <0.001 0.81 (0.76–0.87) <0.001 0.65 (0.59–0.73) <0.001
Brain Met
 No Ref 1.0 Ref 1.0 Ref 1.0
 Yes 3.00 (2.69–3.35) <0.001 2.65 (2.37–2.96) <0.001 1.77 (1.51–2.08) <0.001
Liver Met
 No Ref 1.0 Ref 1.0 Ref 1.0
 Yes 2.06 (1.93–2.21) <0.001 2.15 (2.00–2.32) <0.001 1.21 (1.08–1.36) 0.001
Lung Met
 No Ref 1.0 Ref 1.0 Ref 1.0
 Yes 1.75 (1.64–1.87) <0.001 1.80 (1.68–1.93) <0.001 1.20 (1.08–1.33) 0.001
Surgery
 No surgery Ref 1.0 Ref 1.0 Ref 1.0
 PM 0.41 (0.36–0.47) <0.001 0.38 (0.33–0.45) <0.001 0.69 (0.56–0.85) <0.001
 TM 0.33 (0.28–0.38) <0.001 0.31 (0.26–0.38) <0.001 0.57 (0.44–0.73) <0.001
 RM 0.29 (0.26–0.33) <0.001 0.32 (0.28–0.37) <0.001 0.38 (0.31–0.48) <0.001
 Others 0.38 (0.18–0.79) 0.009 0.30 (0.12–0.76) 0.011 0.85 (0.31–2.37) 0.756

SEER – Surveillance, Epidemiology, and End Result; OR – odds ratio; CI – confidence interval; Ref – reference; NA – not applicable; UOQ – upper outer quadrant; LOQ – lower outer quadrant; LIQ – lower inner quadrant; UIQ – upper inner quadrant; CEN – central portion; NOS – not otherwise specified; PM – partial mastectomy; TM – total mastectomy; RM – radical mastectomy.